Pfizer and AstraZeneca a Marriage Not to Be – Yet?

Stephen Archer
Posted: 08/18/2014

Mergers and acquisitions may excite the markets and shareholders on both sides but their record of success in delivering the anticipated benefits is not good. Around 80% fail on the key measures of synergies, costs savings and growth in shareholder value. No matter if they are small medium or large, mergers hold high risks. Nonetheless,

To continue viewing this content please fill out the form below and become an Pharma IQ member.
Or if you're already a Pharma IQ member, sign in below to download.

By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product and you agree to our User Agreement, Privacy Policy, and Cookie Policy.

Stephen Archer
Posted: 08/18/2014

Pharma IQ Members


The Hurlingham Club, London, United Kingdom
January 21 - 23, 2018
Twickenham Stadium, London, United Kingdom
January 28 - 31, 2018